S'abonner

Insulin-like growth factors and cancer - 01/09/11

Doi : 10.1016/S1470-2045(02)00731-3 
Gregor Fürstenberger, Dr a,  : Senior Oncology Research Fellow, Hans-Jörg Senn b : Professor and Chairman
a Medical Oncology, Center for Tumour Detection and Prevention, St Gallen, Switzerland 
b Center for Tumour Detection and Prevention, St Gallen, Switzerland 

* Correspondence: Dr Gregor Fürstenberger, Senior Oncology Research Fellow, Center for Tumour Detection and Prevention, Rorschacherstrasse 150, CH-9006 St. Gallen, Switzerland. Tel: + 41 71 243 0043. Fax: + 41 71 243 0044

Summary

Interest in insulin-like growth factors (IGFs) and their effect on carcinogenesis has increased recently because high serum concentrations of IGF1 are associated with an increased risk of breast, prostate, colorectal, and lung cancers. Physiologically, IGF1 is the major mediator of the effects of the growth hormone; it thus has a strong influence on cell proliferation and differentiation and is a potent inhibitor of apoptosis. The action of IGF1 is predominantly mediated through the IGF1 receptor (IGF1R). IGF1R is involved in several oncogenic transformation processes. The availability of unbound IGF1 for interaction with IGF1R is modulated by IGF-binding proteins (IGFBP1–6). IGFBPs, especially IGFBP3, have independent effects on cell growth, for example, IGFBP3 has proapoptotic activities both dependent on and independent of p53.

Le texte complet de cet article est disponible en PDF.

Plan


© 2002  Elsevier Ltd. Tous droits réservés.© 2002  Courtesy of AG Renehan, CRC Paterson Institute for Cancer Research, UK. Publié par Elsevier Masson SAS. Tous droits réservés.© 2002  1997 Massachusetts Medical Society. All rights reserved. Publié par Elsevier Masson SAS. Tous droits réservés.© 2002  Courtesy of BioCarta. Publié par Elsevier Masson SAS. Tous droits réservés.
Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 3 - N° 5

P. 298-302 - mai 2002 Retour au numéro
Article précédent Article précédent
  • A case for geriatric oncology
  • Lazzaro Repetto, Lodovico Balducci
| Article suivant Article suivant
  • Hormone-replacement therapy and breast cancer
  • Jo Marsden

Déjà abonné à cette revue ?